Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the Phase III LEAD-1 trial in 1,026 patients, all 3 doses of liraglutide met the primary endpoint of improved glucose control from
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury